Cost of new “miracle” pancreatic cancer pill sparks concern

A pill that can nearly double survival time for pancreatic cancer patients now carries a price tag of almost $480,000 a year.

Story Snapshot

The Food and Drug Administration (FDA) approved Rasonque (daraxonrasib) on August 26, 2026, for adults with advanced pancreatic cancer.
Revolution Medicines set the price at about $39,800 for a 30-day supply, or roughly $477,000 a year.
Patients on the drug lived a median of 13.2 months, compared to 6.7 months on standard chemotherapy.
Medicare covers most pancreatic cancer patients, but the company’s coupons that cut costs to zero do not apply to Medicare.
The price fits a wider pattern in cancer care, where new drugs increasingly launch above $100,000 a year.

FDA Clears First-of-Its-Kind Treatment

The FDA approved Rasonque for adults with metastatic pancreatic adenocarcinoma who already tried one treatment or cannot handle combination chemotherapy. The agency called it a new option for a cancer that kills quickly and has few good treatments. The drug works by blocking a protein pathway called RAS, which drives many pancreatic tumors. Regulators cleared it months ahead of schedule.

Clinical trial results show why doctors are excited. Patients taking daraxonrasib lived a median of 13.2 months, almost double the 6.7 months seen with chemotherapy alone. The risk of death dropped by 60% compared to standard treatment, based on the trial’s hazard ratio. For a cancer where five-year survival rates remain grim, those numbers stand out as a real gain.

A Price That Stunned Even Wall Street

Revolution Medicines told federal regulators the wholesale price is about $39,800 for a month’s supply. That works out to roughly $477,000 a year before insurance, discounts, or rebates apply. The New York Times noted the sticker price comes to about $663 per tablet, calling it part of a “new normal” for cancer drug pricing that would have seemed unthinkable a decade ago.

Coverage of the price has focused heavily on that headline number. A CBS Mornings report noted the annual cost runs close to $500,000 and creates real financial strain for families. Commercial insurance may cover much of the cost with varying copays, and manufacturer coupons can bring some patients’ out-of-pocket costs to zero.

The Medicare Gap Worries Older Patients

Those coupons come with a major catch. They do not apply to Medicare, the program that covers about 70% of pancreatic cancer patients, most of whom are over 65. That leaves a large share of the sickest patients without access to the price relief available to people on private insurance. A patient advocacy group notes that Medicare and Medicaid usually cover FDA-approved drugs once cleared, but coverage rules and out-of-pocket costs still vary widely by plan.

Pancreatic cancer patients already faced steep bills before this approval. Older studies found that oral cancer drugs like erlotinib cost patients median out-of-pocket payments near $16,000, on top of other treatment expenses. That history shows financial strain on pancreatic cancer patients is not new, but the size of this latest price jump has intensified the debate over what patients and insurers can reasonably absorb.

$RVMD — First FDA approval for Revolution Medicines. Daraxonrasib (Rasonque) is now approved for adults with metastatic pancreatic cancer. This validates the RVMD RAS-targeting platform, removing a major regulatory risk.

The approval is based on a 500-patient study. Rasonque…

— Banancial (@Banancial) August 26, 2026

Part of a Bigger Pattern in Cancer Care

Rasonque’s price is not an outlier. Researchers found that in 2023, launch prices topped $100,000 a year for 95% of new anticancer drugs approved that year. That means sky-high starting prices have become the industry standard rather than the exception, leaving patients, insurers, and lawmakers to keep fighting the same battle over affordability with each new breakthrough that reaches the market.

The clash between medical progress and sticker shock leaves patients and families caught in the middle, regardless of political leanings. Conservatives and liberals alike have raised concerns for years about drug companies, insurers, and government programs failing to align on what patients can actually afford. Rasonque’s approval offers real hope for a brutal disease, but its price tag reopens a debate that Washington has yet to resolve.